The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Research has found a connection between weight loss drugs such as Ozempic and Zepbound and serious eye conditions, leading to concerns about "Ozempic blindness." The exact reason for this association ...

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several people who developed eye conditions soon after they began taking semaglutide ...